Last reviewed · How we verify
Cytokine release syndrome induced by tumor-specific T-cell infusion therapy
Approved treatments
- Roactemra · Roche
Roactemra works by blocking the interleukin-6 receptor, a protein that plays a key role in inflammation.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Cytokine release syndrome induced by tumor-specific T-cell infusion therapy patent landscape — cliff calendar, originator estates, attackable patents
- Cytokine release syndrome induced by tumor-specific T-cell infusion therapy treatment landscape brief
- Cytokine release syndrome induced by tumor-specific T-cell infusion therapy treatment updates RSS
Frequently asked questions about Cytokine release syndrome induced by tumor-specific T-cell infusion therapy
What drugs treat Cytokine release syndrome induced by tumor-specific T-cell infusion therapy?
Tracked treatments include Roactemra.
What is the treatment for Cytokine release syndrome induced by tumor-specific T-cell infusion therapy?
Standard treatment for Cytokine release syndrome induced by tumor-specific T-cell infusion therapy includes Roactemra. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Cytokine release syndrome induced by tumor-specific T-cell infusion therapy patent cliff · Cytokine release syndrome induced by tumor-specific T-cell infusion therapy CI report
- Treatment: Roactemra · Roche
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing